Sebnem Pırıldar, MD: A Preliminary Open-Label Study of Moclobemide Treatment of Pain Disorder

Name: Sebnem Pırıldar, MD: A Preliminary Open-Label Study of Moclobemide Treatment of Pain Disorder
SKU: 2970
Price: 30.00 USD
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 37 No. 3 Articles Tags: berna-zileli, hayriye-elbi, maoi, meltem-uyar, moclobemide, pain, rima, sebnem-pirildar, somatoform-disorders, ülkü-sezgin

Description

Sebnem Pırıldar, MD: A Preliminary Open-Label Study of Moclobemide Treatment of Pain Disorder

Description

Sebnem Pırıldar, MD

GENERAL PSYCHOPHARMACOLOGY

A Preliminary Open-Label Study of Moclobemide Treatment of Pain Disorder

Sebnem Pırıldar, MD, Ülkü Sezgin, MD, Hayriye Elbi, MD, Meltem Uyar, MD, and Berna Zileli, MD

Ranga Krishnan, MB, ChB: Evidence-Based Decision-Making in Psychopharmacology

The Prescriber’s Guide to the MAOI Diet—Thinking Through Tyramine Troubles

On the Origins of MAOI Misconceptions: Reaffirming their Role in Melancholic Depression

Quetiapine XR Negative Clinical Trials Report by Gang Wang

Sebnem Pırıldar, MD: A Preliminary Open-Label Study of Moclobemide Treatment of Pain Disorder

Description

Sebnem Pırıldar, MD

GENERAL PSYCHOPHARMACOLOGY

A Preliminary Open-Label Study of Moclobemide Treatment of Pain Disorder

Sebnem Pırıldar, MD, Ülkü Sezgin, MD, Hayriye Elbi, MD, Meltem Uyar, MD, and Berna Zileli, MD

Related products

Ranga Krishnan, MB, ChB: Evidence-Based Decision-Making in Psychopharmacology

The Prescriber’s Guide to the MAOI Diet—Thinking Through Tyramine Troubles

On the Origins of MAOI Misconceptions: Reaffirming their Role in Melancholic Depression

Quetiapine XR Negative Clinical Trials Report by Gang Wang